Fig. 4
From: Recombinant human endostatin combined with radiotherapy inhibits colorectal cancer growth
Results of western blotting. a: control; b: endostatin; c: radiotherapy; d: radiotherapy with endostatin treatment; e: VEGF gray value-to-GAPDH gray value ratio in each group at 16 days after treatment, a P < 0.05 versus control; b P < 0.05 versus radiotherapy (n = 8 per group). The western blotting results also indicated that VEGF expression was significantly increased in the radiotherapy group and significantly decreased in the endostatin and radiotherapy with endostatin treatment groups compared with the control group (n = 8 per group, P < 0.05) (200×)